JP Morgan 2025: AbbVie's Strategy with Skyrizi and Rinvoq to Compensate for Humira's Decline

AbbVie is strategically positioning Skyrizi and Rinvoq to mitigate the financial impact expected from the patent expiration of Humira. The company has recently shared promising results from the pivotal Phase III TEMPO-1 trial of tavapadon, a treatment for Parkinson’s disease. The trial met its primary endpoint, showing a statistically significant improvement in the MDS-UPDRS Parts II and III combined score at week 26, which could surpass the expectations set by the disease model and significantly contribute to the company's growth in the coming decade.

In addition to its internal developments, AbbVie has entered into an option-to-license agreement with Simcere Zaiming for the development of SIM0500, an investigational drug candidate. This partnership could see Simcere Zaiming receiving up to $1.055bn in upfront payments, option fees, and milestone payments. Furthermore, AbbVie has expanded its collaboration with AbCellera to include the discovery of T-cell engagers (TCE) for oncology applications, indicating a broadening of its research and development efforts in the fight against cancer.